PROteomics and METabolomics Platform - Grenoble - France
The Promethee Proteomics Platform, initially funded by the Auvergne-Rgône-Alpes region and the CLARA Canceropole, provides services and realizes proteomic research projects for the academic and industrial research laboratories. The platform is localized in the Institute of Biology and Pathology (IBP) of the Centre Hospitalier Universitaire Grenoble Alpes and is a research platform of the University Grenoble Alpes linked to the Laboratoire de Biologie Fondamentale et Appliquée (LBFA U1055).

The platform consists of equipments, tools and methods necessary to proteomics studies and the development of methodologies required for protein biomarker research and more fundamental research on the mechanisms involved in cancer or other diseases. The main objectives of the platform are focused on the identification of peptides and proteins, the study of post-translational modifications and protein quantification from various, more or less complex samples (purified proteins, cell lysates, serum, plasma, secretome, tissues,.. ) and particularly clinical samples. Recent efforts are also oriented to the development of complementary methods on metabolomics. The platform participates in the development of systemic approaches (Systems Biology and Systems Medicine), through research programs like SYSCLAD european project.

Several formations are organized by the scientific staff of the platform, from basic courses on proteins for undergraduated students to very specialized practical sessions for graduated students. Promethee platform is involved in the European Graduate School BioHealth Computing by organizing theoretical and practical proteomics courses  and provide internships for master and PhD students. 

The platform is labeled by the GIS IBiSA since 2010 under GPI "Grenoble Proteomic Infrastructure".
Last publications

Actiflagelin, a new sperm activator isolated from Walterinnesia aegyptia venom using phenotypic screening. 
Abd El-Aziz TM, Al Khoury S, Jaquillard L, Triquigneaux M, Martinez G, Bourgoin-Voillard S, Sève M, Arnoult C, Beroud R, De Waard M. 
J Venom Anim Toxins Incl Trop Dis. 2018 Jan 23;24:2.
Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome. 
Danger R, Royer PJ, Reboulleau D, Durand E, Loy J, Tissot A, Lacoste P, Roux A, Reynaud-Gaubert M, Gomez C, Kessler R, Mussot S, Dromer C, Brugière O, Mornex JF, Guillemain R, Dahan M, Knoop C, Botturi K, Foureau A, Pison C, Koutsokera A, Nicod LP, Brouard S, Magnan A; COLT and SysCLAD Consortia. 
Front Immunol. 2018 Jan 11;8:1841.
Isolation and characterization of an anti-leishmanial disintegrin from Cerastes cerastes venom.
Allane D, Oussedik-Oumehdi H, Harrat Z, Seve M, Laraba-Djebari F.
J Biochem Mol Toxicol. 2017 Dec 26.
Low-molecular-weight color pI markers to monitor on-line the peptide focusing process in OFFGEL fractionation. 
Michelland S, Bourgoin-Voillard S, Cunin V, Tollance A, Bertolino P, Slais K, Seve M. 
Electrophoresis. 2017 Aug;38(16):2034-2041.
Tubulin Beta-3 Chain as a New Candidate Protein Biomarker of Human Skin Aging: A Preliminary Study. 
Lehmann SG, Bourgoin-Voillard S, Seve M, Rachidi W. 
Oxid Med Cell Longev. 2017;2017:5140360.
The platform is member of the European Graduate School BioHealth Computing